- Home
- ALLK vs ABOS Comparison
ALLK vs ABOS Comparison
Compare ALLK & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLK
- ABOS
- Stock Information
- Founded
- ALLK 2012
- ABOS 1996
- Country
- ALLK United States
- ABOS United States
- Employees
- ALLK N/A
- ABOS N/A
- Industry
- ALLK Biotechnology: Pharmaceutical Preparations
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- ALLK Health Care
- ABOS Health Care
- Exchange
- ALLK Nasdaq
- ABOS Nasdaq
- Market Cap
- ALLK 101.0M
- ABOS 99.1M
- IPO Year
- ALLK 2018
- ABOS 2021
- Fundamental
- Price
- ALLK $0.86
- ABOS $1.65
- Analyst Decision
- ALLK Hold
- ABOS Strong Buy
- Analyst Count
- ALLK 4
- ABOS 3
- Target Price
- ALLK $1.67
- ABOS $9.33
- AVG Volume (30 Days)
- ALLK 827.7K
- ABOS 412.7K
- Earning Date
- ALLK 03-13-2025
- ABOS 11-12-2024
- Dividend Yield
- ALLK N/A
- ABOS N/A
- EPS Growth
- ALLK N/A
- ABOS N/A
- EPS
- ALLK N/A
- ABOS N/A
- Revenue
- ALLK N/A
- ABOS N/A
- Revenue This Year
- ALLK N/A
- ABOS N/A
- Revenue Next Year
- ALLK N/A
- ABOS N/A
- P/E Ratio
- ALLK N/A
- ABOS N/A
- Revenue Growth
- ALLK N/A
- ABOS N/A
- 52 Week Low
- ALLK $0.54
- ABOS $1.53
- 52 Week High
- ALLK $1.69
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- ALLK 35.16
- ABOS 39.18
- Support Level
- ALLK $0.81
- ABOS $1.54
- Resistance Level
- ALLK $1.00
- ABOS $1.75
- Average True Range (ATR)
- ALLK 0.13
- ABOS 0.13
- MACD
- ALLK -0.03
- ABOS 0.01
- Stochastic Oscillator
- ALLK 8.43
- ABOS 28.57
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.